Xenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Nov 07, 2017 21:57 pm UTC| Business
BURNABY, British Columbia, Nov. 07, 2017 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended September 30, 2017, and...
Tactile Systems Technology, Inc. Reports Third Quarter 2017 Financial Results; Updates 2017 Outlook
Nov 07, 2017 21:55 pm UTC| Business
MINNEAPOLIS, Nov. 07, 2017 -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today...
Innospec Reports Third Quarter 2017 Financial Results
Nov 07, 2017 21:45 pm UTC| Business
Net sales up 62 percent; Net income and adjusted EBITDA more than doubled Strong sales growth in all core businesses Excellent cash generation; Net debt further reduced Annual dividend up 15 percent; Eighth successive...
Profound Medical Corp. Announces Third Quarter 2017 Financial Results
Nov 07, 2017 21:45 pm UTC| Business
TORONTO, Nov. 07, 2017 -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance...
Kornit Digital Reports 2017 Third Quarter Results
Nov 07, 2017 21:41 pm UTC| Business
Highlights GAAP third quarter 2017 revenues of $28.5 million reflects pre-announced delay of a large customer order. Non-GAAP third quarter 2017 revenues of $28.6 million, compared to the prior year period of $30.9...
Farmer Bros. Co. Reports First Quarter Fiscal 2018 Financial Results
Nov 07, 2017 21:41 pm UTC| Business
NORTHLAKE, Texas, Nov. 07, 2017 -- Farmer Bros. Co. (NASDAQ:FARM) (the "Company") today reported financial results for its first fiscal quarter ended September 30, 2017. First Quarter Fiscal 2018 Highlights: Volume...
ChemoCentryx Reports Third Quarter 2017 Financial Results and Recent Highlights
Nov 07, 2017 21:40 pm UTC| Business
-- Phase III ADVOCATE trial of avacopan remains on track to complete enrollment in mid-2018 -- -- Patient enrollment ongoing in registration-supporting trial for avacopan in the treatment C3 Glomerulopathy (C3G) -- --...
FDA Approval of Opdivo Injection Sparks Hope for Cancer Patients with Revolutionary Treatment Update